Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, adenocarcinoma of the pancreas
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically proven adenocarcinoma of the exocrine pancreas excluding periampullary cancer Resectable malignancy must be located in a region that can be encompassed by a radiation port of 20 x 20 cm No evidence of extranodal metastatic disease PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Not specified Renal: Bilateral renal function as demonstrated by excretory urogram (IVP) or abdominal CT scan with contrast OR Greater than 2/3 of one functioning kidney must be shielded during radiation therapy Other: Must have adequate oral nutrition (greater than 1200 calories daily) Greater than 5 years since prior malignancy except: Squamous cell skin cancer Basal cell skin cancer In situ cervical cancer Not pregnant or lactating Patients of reproductive potential must use effective birth control No cystic neoplasms of the pancreas No islet cell, periampullary or cholangiocarcinoma No Federal Medical Center inmates PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for this disease Endocrine therapy: Not specified Radiotherapy: No prior radiation therapy for this disease No prior radiation therapy to the abdomen Surgery: Celiotomy and standardized exploration for resectability required
Sites / Locations
- Mayo Clinic Cancer Center